Sydney Jennings

Phase 3 LUCIDITY results showed avexitide reduced Level 2 and Level 3 hypoglycemic events by 55% vs placebo in post-bariatric hypoglycemia.

Stepped reminders to PCPs and patients increased annual lung cancer screening adherence by 27.7 percentage points, according to new research.

A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.

Relationship-based navigation helped more primary care patients access health and social services than referral to a free information service.

The US FDA granted breakthrough device status to Freenome’s investigational blood test designed to triage high-risk adults for lung cancer screening.

The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.

Insulin icodec is now available in the US after FDA approval, offering adults with type 2 diabetes a once-weekly basal insulin option.

Topline phase 2 data showed single-dose ABCL635 reduced moderate-to-severe vasomotor symptom frequency by 83% at week 4.

FDA acceptance starts review of clesrovimab for second-season RSV prevention in high-risk children younger than 2 years.

The FDA approved oveporexton for narcolepsy type 1 in adults, marking the first orexin receptor agonist targeting the underlying biological cause of narcolepsy.

FDA approved Mucinex 12HR Cold & Fever Multi-Symptom, an OTC product combining guaifenesin, dextromethorphan, and naproxen sodium.

FDA approval of centanafadine could expand ADHD treatment for patients aged 6 years or older, but labeling and pivotal data remain unavailable.

A McGill University–led team developed a prediction model integrating pregnancy-related factors to identify cardiovascular disease risk in women aged 15 to 45.

Recent FDA actions include approvals and clearances in lipid management, CRC screening, contraception, vaginitis testing, and Alzheimer psychosis.

FDA cleared Roche’s cobas BV/CV assay to detect bacterial vaginosis and Candida vaginitis from a single vaginal swab sample.

Topline TRIUMPH-2 and TRIUMPH-3 results showed retatrutide reduced weight by up to 20.8% in adults with type 2 diabetes and 22.6% in adults with CVD.

The US FDA Fast Track status advances remlifanserin for Alzheimer disease psychosis, with phase 2 RADIANT data expected in fall 2026.

A peer-reviewed study found FDA-cleared IGeneX immunoblot tests detected 58.3% of early Lyme cases vs 30.0% with standard two-tier testing.

A new study links semaglutide and tirzepatide to fewer alcohol-related hospitalizations in adults with AUD and diabetes or obesity.

A cross-sectional study linked compulsive smartphone use and limited offline social activity to depressive symptoms in adults aged 60 years or older.

ACOG updated HIV screening and prevention guidance, recommending opt-out lifetime HIV testing and stronger PrEP counseling and prescribing.

A new analysis estimates the 2026 dyslipidemia guideline expands primary prevention statin eligibility to 87.5 million US adults.

FDA accepted Shionogi’s sNDA for cefiderocol for pediatric HABP/VABP and complicated UTI caused by certain Gram-negative bacteria.

The US FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor, to reduce LDL-C in adults with hypercholesterolemia, including HeFH.

FDA accepted Axsome’s NDA for AXS-12 for cataplexy in narcolepsy and set a PDUFA target action date of May 1, 2027.

Once-weekly subcutaneous lecanemab matched IV initiation exposure in early Alzheimer disease, but comparative clinical outcome data remain limited.

The 2026 global status report on cancer projects nearly 35 million new cases annually by 2050 and underscores urgent action on prevention and care access.

AI-generated portal message drafts often missed clinical context and required physician editing in a Dartmouth analysis.

Phase 2 TRAPEDS-1 trial data show tralokinumab produced consistent pharmacokinetics and tolerability in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.

Catch up on the 7 FDA drug approvals most relevant to primary care, including new options for hypertension, weight management, acne, and more.